Pharmacovigilance Market Size, Share & Trends Analysis Report By Type, By Service Provider, By Clinical Trial Phase, By Therapeutic Area, By End-User, By Region And Segment Forecasts 2026 – 2035

Pharmacovigilance refers to the practices and processes involved in monitoring the safety of pharmaceutical products, detecting adverse effects, and ensuring regulatory compliance to protect public health.

Key factors include rising adverse drug reactions, stringent regulations, technological advancements like AI, and expanding pharmaceutical R&D activities.

The market is projected to grow from USD 9.61 billion in 2026 to USD 21 billion by 2035.

The CAGR is expected to be 8.8% from 2026 to 2035.

North America will contribute notably, holding around 42.5% of the market value due to advanced regulations and high R&D investments.

Major players include IQVIA, Accenture, Cognizant, ICON, Parexel, ArisGlobal, Capgemini, Wipro, IBM, and Labcorp.

The report provides in-depth analysis of market size, trends, segments, key players, regional insights, and forecasts from 2026 to 2035.

Stages include data collection, case processing, signal detection, risk assessment, regulatory reporting, and ongoing surveillance.

Trends lean toward AI automation and real-world data, while preferences shift to patient-centric reporting and outsourced services for efficiency.

Stringent FDA and EMA guidelines, along with environmental concerns like data privacy under GDPR, are key influencers driving compliance-focused growth.